Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

January 2022; 9 (1) Clinical/Scientific NoteOpen Access

Nicolau Syndrome After Glatiramer Acetate Injection in Close Proximity to Administration of SARS-CoV-2 mRNA Vaccine

Michael Yu Sy, Erin Fromm, Linda Doan, Nathan Rojek, Alexander Ulrich Brandt
First published November 10, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001112
Michael Yu Sy
From the Department of Neurology (M.Y.S., E.F., U.B), Department of Pathology (L.D.), and Department of Dermatology (N.R.), University of California, Irvine.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin Fromm
From the Department of Neurology (M.Y.S., E.F., U.B), Department of Pathology (L.D.), and Department of Dermatology (N.R.), University of California, Irvine.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda Doan
From the Department of Neurology (M.Y.S., E.F., U.B), Department of Pathology (L.D.), and Department of Dermatology (N.R.), University of California, Irvine.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan Rojek
From the Department of Neurology (M.Y.S., E.F., U.B), Department of Pathology (L.D.), and Department of Dermatology (N.R.), University of California, Irvine.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Ulrich Brandt
From the Department of Neurology (M.Y.S., E.F., U.B), Department of Pathology (L.D.), and Department of Dermatology (N.R.), University of California, Irvine.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Nicolau Syndrome After Glatiramer Acetate Injection in Close Proximity to Administration of SARS-CoV-2 mRNA Vaccine
Michael Yu Sy, Erin Fromm, Linda Doan, Nathan Rojek, Alexander Ulrich Brandt
Neurol Neuroimmunol Neuroinflamm Jan 2022, 9 (1) e1112; DOI: 10.1212/NXI.0000000000001112

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
834

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Nicolau syndrome (synonym: embolia cutis medicamentosa) is a rare complication of subcutaneous and IM drug injections, typically independent of the drug itself.1 Patients develop painful purpuric and necrotizing lesions at the injection site, often requiring surgical intervention. The pathogenesis of the ischemic skin necrosis is poorly understood. We report 2 cases of skin necrosis associated with injection of glatiramer acetate (GA) in patients with multiple sclerosis (MS), which occurred in close temporal relation to the second dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) mRNA vaccine.

Case 1

A 62-year-old man with a history of hyperlipidemia, obesity (body mass index of 30.1 kg/m2), and MS received the first dose of the BNT162b2 vaccine in late March 2021.2 The patient had been stable on GA 40 mg three times a week (Glatopa) for the past 5 years without new MRI lesions or relapses and no serious injection reactions. An injection of GA given in the lateral abdomen 17 days after the first vaccine dose resulted in retiform purpura surrounding the injection site (Figure, A). The purpura appeared 1 day before the second dose of the BNT162b2 vaccine and subsequently continued to spread (Figure, B). The injection site developed a necrotic black eschar (Figure, C). A punch biopsy obtained 14 days after vaccine dose 2 contained fibrin thrombi in the superficial and deep dermis, along with tissue necrosis indicative of thrombotic vasculopathy (Figure, D). Continued administration of GA after appearance of purpura did not lead to any further injection site reactions.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Development of Retiform Purpura With Central Necrosis After Injection of Glatiramer Acetate (GA) in Close Association With Administration of BNT162b2 (A–D) and mRNA-1273 Vaccine (E and F)

(A–C) Days 2 (A), 5 (B), and 14 (C) after injection of GA in close association with the BNT162b2 vaccine. (D) Representative micrograph of punch biopsy of cutaneous lesion revealing intravascular fibrin thrombi at day 14 (×200). (E and F) Four weeks (E) and 5 weeks (F) after GA injection in close association with the mRNA-1273 vaccine.

Case 2

A 59-year-old woman with a history of hypertension and MS received the first dose of the mRNA-1273 vaccine in early March 2021.3 The patient had been stable on GA 40 mg three times a week (Copaxone) for more than 10 years without new MRI lesions or relapses. One week after the first vaccine dose, a large welt developed at the site of a GA injection near her right hip. Over the next few weeks, retiform purpura developed around the injection site. A central necrotic eschar developed when she received the second dose of the mRNA-1273 vaccine 4 weeks later, which enlarged over the next 7 days (Figure, E and F). She developed severe burning pain at the site of the wound, and the wound was debrided. Her local dermatologist diagnosed her with Nicolau syndrome but did not perform a biopsy. GA injections continued at other sites throughout the development of this purpuric skin lesion without further reactions. Roughly 10 years ago, she had experienced 1 skin reaction after GA injection that did not develop into the large ischemic lesion observed in the current case.

Discussion

The COVID-19 pandemic has placed enormous health and economic burden on the worldwide community. The mRNA vaccines from Pfizer (BNT162b2) and Moderna (mRNA-1273) are notable achievements, highly effective in preventing severe COVID-19 syndromes.2,3 Our second patient reported typical side effects including fever, fatigue, headache, chills, and muscle pain, whereas the first patient had no side effects. Complications related to drug interactions in specific populations have not been reported.

Nicolau syndrome is an exceedingly rare, adverse event in GA-treated patients with MS.1,4 Occurrence of Nicolau syndrome in 2 patients with MS at our MS center in close proximity to SARS-CoV2 vaccination with mRNA vaccines raises the possibility of an association between the 2. No other reports of similar skin lesions were observed in our vaccine program at UC Irvine. Our MS center currently has 224 patients on GA, with an estimated 70%–80% having received a SARS-CoV2 vaccine. Of interest, the joint targets of both interventions are professional antigen-presenting dendritic cells (DCs): mRNA vaccines work via mRNA delivery to DCs at the injection site, which then produce and present mRNA-encoded viral antigen to initiate an immune response.5 Although the mechanisms of GA on the immune system are broad, DCs act as the initial target for drug uptake and presentation.6 Both patients have been stable on GA, and both tested positive for antibodies against SARS-CoV2 4 months after vaccination.

We report these cases to make MS centers aware of this potential complication. Although our 2 observations are by no means a proof of causation, they suggest that providers and patients should carefully monitor GA injections in close proximity to SARS-CoV2 vaccinations with mRNA vaccine. A timely response coordinated with dermatology has been reported to prevent necrosis and scar formation, but it is unclear whether this approach may also be successful under these new circumstances.7 Of note, our observation may also be of relevance for other injectables, as Nicolau syndrome has also been observed with other substances, and may be attributed to mechanical affection of the tissue rather than to drug-related effects.

Study Funding

No targeted funding reported.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by the authors.

  • Received April 30, 2021.
  • Accepted in final form August 30, 2021.
  • Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Kimbrough DJ,
    2. Newsome SD
    . Case report: two cases of Nicolau syndrome associated with glatiramer acetate. Int J MS Care. 2017;19(3):148-150.
    OpenUrl
  2. 2.↵
    1. Polack FP,
    2. Thomas SJ,
    3. Kitchin N, et al
    . Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(3):2603-2615.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Baden LR,
    2. Sahly HME,
    3. Essink B, et al.
    Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(3):403-416.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Bosca I,
    2. Bosca M,
    3. Belengeur A, et al.
    Necrotising cutaneous lesions as a side effect of glatiramer acetate. J Neurol. 2006;253(3):1370-1371.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Pardi N,
    2. Hogan MJ,
    3. Porter FW,
    4. Weissman D.
    mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018;17(3):261-279.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Prod'homme T,
    2. Zamvil SS.
    The evolving mechanisms of action of glatiramer acetate. Cold Spring Harb Perspect Med. 2019;9(3):a029249.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Geukens J,
    2. Rabe E,
    3. Bieber T.
    Embolias cutis medicamentosa of the foot after sclerotherapy. Eur J Dermatol. 1999;9(3):132-133.
    OpenUrlPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Case 1
    • Case 2
    • Discussion
    • Study Funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials

Dr. Nicole Sur and Dr. Mausaminben Hathidara

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • Multiple sclerosis
  • COVID-19

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (4)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise